Intervention

Alemtuzumab

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 25 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials25

Recruiting3

Common conditions25

Lead sponsors shown15

Clinical trials

25 shown

Autologous Stem Cell Transplantation in Patients With Systemic SclerosisNCT03630211 · 2018-07-31

Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureNCT03500731 · 2018-04-19

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTNCT01962415 · 2014-02-04

ADAs to AlemtuzumabNCT06310343 · 2022-07-12

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesNCT05688436 · 2021-09-24

ACTIVE_NOT_RECRUITING

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled TrialNCT04971005 · 2021-08-27

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple SclerosisNCT03135249 · 2018-05-01

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)NCT03477500 · 2018-03-21

ACTIVE_NOT_RECRUITING

Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)NCT03182426 · 2017-08-15

Neurofilaments for NEDA Assessing in MSNCT03250169 · 2017-08-01

Physical and Cognitive Performance During the Two First Years of Lemtrada TreatmentNCT03806387 · 2017-03-01

The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis PatientsNCT03193086 · 2017-01-01

Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)NCT02529839 · 2015-10-01

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective PotentialNCT02419378 · 2015-06-01

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantNCT02061800 · 2013-06-03

High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior TreatmentNCT01679041 · 2012-11-01

Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced SubjectsNCT01624714 · 2012-09-01

Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple SclerosisNCT01712945 · 2012-06-01

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple SclerosisNCT01395316 · 2011-06-01

Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis PatientsNCT01333358 · 2011-05-01

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OneNCT00530348 · 2007-08-01

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaNCT00328198 · 2006-05-01

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas TransplantationNCT00331162 · 2005-02-01

Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney TransplantationNCT00177138 · 2004-07-01

Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based StudyNCT06705608 · 2003-01-01

Common conditions

Leading sponsors

Paul Szabolcs 3 Genzyme, a Sanofi Company 2 Queen Mary University of London 2 Biogen 1 Cambridge University Hospitals NHS Foundation Trust 1 Central Texas Neurology Consultants 1 Diane George 1 Glostrup University Hospital, Copenhagen 1 Hadassah Medical Organization 1 Haukeland University Hospital 1 Samuel Forrester Hunter, MD, PhD 1 Seah Lim M.D. 1 Universitätsklinikum Hamburg-Eppendorf 1 University Hospital Muenster 1 University of Aarhus 1

Trial status mix

COMPLETED10

TERMINATED5

UNKNOWN5

RECRUITING3

ACTIVE_NOT_RECRUITING2

Phase mix

PHASE29

PHASE15

PHASE45

PHASE33

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.